Additionally, ANXA1 targeting could be useful, considering that it promotes the progression and metastasis of nasopharyngeal carcinoma through the stabilization of ephrin type-A receptor 2 (EphA2) [89], and that exosomal ANXA1 is driving the malignant transformation of thyroid cells in thyroid cancer [32]. The gene discussed is EPHA2; the disease is nasopharyngeal carcinoma.